Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well ...

The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod in NCP. NCP is a chronic ocular pain syndrome with no FDA-approved therapies ...

Patients with neuropathic bladder (NB), a condition in which nerve damage affects bladder function, have a significantly ...

Neuropathic pain is a common problem in clinical practice and one that adversely affects patients' quality of life. Converging evidence from animal and human studies demonstrates that neuropathic pain ...

Neuropathic pain is a type of pain caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population. It is often sharper and more intense than other ...

The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with ...

The accepted paper, titled "Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study", will be presented in the Ocular Surface ...

Pain is one of the most debilitating symptoms that presents with neuropathy. Neuropathic pain syndrome is a challenge to treat and, even with appropriate evidence-based treatment, only a 40% reduction ...

A systematic review of 21 studies found no strong evidence for cannabis being able to soothe neuropathic pain. | Cannabis ...

Understanding both sides of this medication is essential before starting or continuing to take it.

Please provide your email address to receive an email when new articles are posted on . It is time for us to address neuropathic eye pain. We can think of neuropathic ...